The discussion about the Anavax Retts syndrome trial results
https://hotcopper.com.au/threads/anavex-meets-endpoints-phase2-rett.5818604/page-3#post-71711938
seems to have tracked into a discussion about Acadia's use of NNZ-2591 for the treatment of Retts syndrome.
"NNZ-2591 to Acadia for Retts syndrome" may have more to do with limiting its use by a third party for Retts syndrome treatment, than it has to do with creating an alternative drug treatment for Acadia (and its associated trial costs).If Acadia was smart, then it's what they have sought.Given the treatment costs, off-label use of NNZ-2591 for treatment of Retts syndrome is unlikely to materialise.
Acadia got Rof Trofenitde AND Global rights for NNZ-2591 for RETT/Fragile X, page-42
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |